Form 4: Centessa Pharmaceuticals CEO Sells Shares Under 10b5-1 Trading Plan

Centessa Pharmaceuticals CEO, Saurabh Saha, sold a portion of his ordinary shares under a pre-arranged 10b5-1 trading plan.

Summary

• Centessa Pharmaceuticals CEO, Saurabh Saha, executed sales of ordinary shares on January 21, 2025.
• A total of 55,000 shares were sold in multiple transactions at weighted average prices of $15.7586 and $16.1937.
• These sales were conducted under a Rule 10b5-1 trading plan adopted on May 16, 2024.
• Following these transactions, Mr. Saha directly owns 429,398 ordinary shares and indirectly owns 38,000 shares through a trust.

Sentiment

Score: 5

Explanation: The document is a routine disclosure of insider trading activity under a pre-arranged plan. It is neither positive nor negative, but a neutral event.

Risks

• Sales by insiders, even under a 10b5-1 plan, can sometimes be perceived negatively by the market.

Industry Context

Insider trading activity is a common occurrence in publicly traded companies, and the use of 10b5-1 plans is a standard practice to avoid accusations of trading on non-public information. This filing is a routine disclosure of such activity.

Comparison to Industry Standards

• The use of a 10b5-1 trading plan is a common practice among executives at publicly traded companies, including those in the pharmaceutical sector such as Pfizer, Moderna, and BioNTech.
• These plans allow for pre-scheduled sales of shares to avoid accusations of insider trading.
• The reported sales are within the typical range of insider transactions and do not appear to be unusual compared to similar filings from other companies.

Stakeholder Impact

• The share sales may have a minor impact on the stock price, but the use of a 10b5-1 plan suggests the sales were not based on any non-public information.

Key Dates

Keywords

Centessa Pharmaceuticals, Saurabh Saha, insider trading, Form 4, 10b5-1 plan, share sale, executive, CNTA